200270-65-1

Basic information

• Product Name: N-[2-(4-Aminophenyl)-1(S)-[4-(2-fluoroethyl)piperidin-1-ylcarbonyl]ethyl]-4-[1(S)-benzyl-2-(4-morpholinyl)ethyl]pyridine-3-sulfonamide
• CAS NO: 200270-65-1
• Molecular Formula: C₃₄H₄₅FN₆O₄S
• Molecular Weight: 652.83795
• Mol File: 200270-65-1.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-[2-(4-Aminophenyl)-1(S)-[4-(2-fluoroethyl)piperidin-1-ylcarbonyl]ethyl]-4-[1(S)-benzyl-2-(4-morpholinyl)ethyl]pyridine-3-sulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[2-(4-Aminophenyl)-1(S)-[4-(2-fluoroethyl)piperidin-1-ylcarbonyl]ethyl]-4-[1(S)-benzyl-2-(4-morpholinyl)ethyl]pyridine-3-sulfonamide(200270-65-1)
• EPA Substance Registry System: N-[2-(4-Aminophenyl)-1(S)-[4-(2-fluoroethyl)piperidin-1-ylcarbonyl]ethyl]-4-[1(S)-benzyl-2-(4-morpholinyl)ethyl]pyridine-3-sulfonamide(200270-65-1)

Safety Data

• Hazardous Substances Data: 200270-65-1(Hazardous Substances Data)

Upstream product

• 200268-11-7 Methanesulfonic acid (S)-2-{3-[(S)-2-[4-(2-fluoro-ethyl)-piperidin-1-yl]-1-(4-nitro-benzyl)-2-oxo-ethylsulfamoyl]-pyridin-4-ylamino}-3-phenyl-propyl ester 
• 200268-10-6 4-((S)-1-Hydroxymethyl-2-phenyl-ethylamino)-pyridine-3-sulfonic acid [(S)-2-[4-(2-fluoro-ethyl)-piperidin-1-yl]-1-(4-nitro-benzyl)-2-oxo-ethyl]-amide 
• 51498-37-4 4-hydroxypyridine-3-sulfonic acid 
• 33263-44-4 4-chloro-pyridine-3-sulfonyl chloride 
• 33305-77-0 Boc-Phe(p-NO₂)-OH 
• 200268-12-8 4-((S)-1-Benzyl-2-morpholin-4-yl-ethylamino)-pyridine-3-sulfonic acid [(S)-2-[4-(2-fluoro-ethyl)-piperidin-1-yl]-1-(4-nitro-benzyl)-2-oxo-ethyl]-amide 
• 221624-33-5 4-Chloro-pyridine-3-sulfonic acid [(S)-2-[4-(2-fluoro-ethyl)-piperidin-1-yl]-1-(4-nitro-benzyl)-2-oxo-ethyl]-amide 

Relevant articles and documents

The discovery of orally available thrombin inhibitors: Studies towards the optimisation of CGH1668

The chemical optimisation of CGH1668 1 is described employing an in vivo model of absorption to determine the influence on bioavailability of single point modifications to five key molecular templates. The discovery of an orally bioavailable and selective thrombin inhibitor, 24, highlights the utility of this approach.